Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna. It employs 400…
History, Companies, Technology & Products
Explore the main themes, entities and connections around Intercell. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
vienna valneva company vaccines ag development merged vivalis se biotechnology austria products people vaccine focused therapeutic infectious diseases form 2012
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Intercell | Defunct | 2013 (2013) | 1.00 | infobox |
| Intercell | Fate | Merged with Vivalis SA | 1.00 | infobox |
| Intercell | Founded | 1998 | 1.00 | infobox |
| Intercell | Headquarters | Vienna, Austria | 1.00 | infobox |
| Intercell | Industry | Biotechnology | 1.00 | infobox |
| Intercell | Key people | Thomas Lingelbach (CEO), Michel Gréco (Chairman of the supervisory board) | 1.00 | infobox |
| Intercell | Net income | (€255.2 million) (2010) | 1.00 | infobox |
| Intercell | Number of employees | 410 (average, 2010) | 1.00 | infobox |
| Intercell | Operating income | (€251.2 million) (2010) | 1.00 | infobox |
| Intercell | Products | Development of vaccines | 1.00 | infobox |
| Intercell | Revenue | €34.2 million (2010) | 1.00 | infobox |
| Intercell | Successor | Valneva SE | 1.00 | infobox |
| Intercell | Total assets | €225.2 million (end 2010) | 1.00 | infobox |
| Intercell | Total equity | €121.1 million (end 2010) | 1.00 | infobox |
| Intercell | Traded as | WBAG: ICLL OTCQX: INRLY | 1.00 | infobox |
| Intercell | Type | Aktiengesellschaft | 1.00 | infobox |
| Intercell | Website | www.intercell.com | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.